However, these mice were BRCA1-proficient and at risk for breast cancer because of overexpression of transgenic erbB2 (Her2), which is a member of the EGFR family and a direct target for the drugs used in those studies, that is, lapatinib or gefitinib. This evidence concerns the gene BRCA1 and breast cancer.